eMedicine Specialties > Emergency Medicine > Toxicology
Toxicity, Disulfiram
Updated: Aug 20, 2008
Introduction
Background
Disulfiram (tetraethylthiuram disulfide [TETD]) has been used for more than 50 years as a deterrent to ethanol abuse in the management of alcoholism. Approximately 200,000 alcoholics take disulfiram, or Antabuse, regularly in the United States.
The first suggestion that disulfiram might be used in the treatment of alcoholism came in 1937 when an American physician noted that workers in the rubber industry who were exposed to TETD developed a reaction after drinking ethanol. A decade later, two Danish researchers at the Royal Danish School of Pharmacy in Copenhagen made the same discovery. Jens Hald and Eric Jacobsen were experimenting with disulfiram as a potential antihelminthic, and each took small doses to determine potential side effects in humans. Several days later, they attended a cocktail party and both became ill. They concluded that the facial flushing and tachycardia they experienced must be due to the disulfiram.
Soon thereafter, physicians began prescribing disulfiram as a deterrent to ethanol abuse. It has also been proposed as a deterrent to cocaine abuse, and several studies have suggested improved retention rates in treatment programs for cocaine-dependent individuals treated with disulfiram. A study found diminished "high" or "rush" after intravenous cocaine administration to healthy volunteers pretreated with disulfiram, with no change in cardiovascular parameters.1
The disulfiram-ethanol reaction (DER) is due to increased serum acetaldehyde concentrations generated by the metabolism of ethanol by alcohol dehydrogenase in the liver. Normally, this acetaldehyde is cleared rapidly by its metabolism to acetate via aldehyde dehydrogenase. Disulfiram blocks this enzyme, irreversibly inhibiting the oxidation of acetaldehyde and causing a marked increase in acetaldehyde concentrations after ethanol consumption. The discomfort associated with this syndrome is intended to serve as a negative stimulus, but the reaction may be severe enough to cause hypotension and death.
In considering disulfiram toxicity, a distinction must be made between the clinical manifestations of a disulfiram-ethanol reaction (DER) and the toxic effects of disulfiram itself. Direct disulfiram toxicity may be further divided into acute poisoning versus chronic poisoning. The directly toxic effects of disulfiram include neurologic, cutaneous, and hepatotoxic sequelae in addition to the disulfiram-ethanol reaction.
Disulfiram received US Food and Drug Administration (FDA) approval for use in the treatment of alcoholism in 1951. At that time, it was commonly prescribed in very high doses, up to 3,000 mg a day in some cases. This resulted in a relatively high rate of extremely severe or fatal reactions. Today, much lower doses are used, and the incidence of disulfiram toxicity has waned.
Pathophysiology
Ethanol is mainly metabolized in the liver to acetaldehyde by alcohol dehydrogenase (ADH). Acetaldehyde is then oxidized to acetate by aldehyde dehydrogenase (ALDH). Disulfiram irreversibly inhibits the oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on ALDH (see Media file 1).
The pathway of ethanol metabolism. Disulfiram reduces the rate of oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on aldehyde dehydrogenase (ALDH).
Ultimately, disulfiram reduces the rate of oxidation of acetaldehyde, causing a 5- to 10-fold increase in the concentration of acetaldehyde. An increased serum acetaldehyde concentration is thought to be responsible for the unpleasant side effects associated with the disulfiram-ethanol reaction.
Disulfiram also directly inhibits hepatic microsomal enzymes (cytochrome P450), in particular CYP2E1. This interferes with the metabolism of certain drugs, most notably that of warfarin, phenytoin, and theophylline. Disulfiram may also decrease the clearance of some benzodiazepines (diazepam, oxazepam, and chlordiazepoxide), caffeine, and some tricyclic antidepressants (desipramine and imipramine). The resulting possible elevation of serum concentrations of these medications has the potential to cause a corresponding toxicity.
Disulfiram is highly lipid soluble (accumulates in adipose tissue, crosses blood-brain barrier), highly protein-bound, and has 80% bioavailability after an oral dose of 350 mg. Approximately 5-20% is not metabolized and is excreted unchanged in the feces; the remainder is metabolized to both toxic and nontoxic metabolites. The elimination of disulfiram and its numerous metabolites is a very slow process. Approximately 20% of the drug remains in the body for 1-2 weeks postingestion. Most of these metabolites are then eliminated through the gastrointestinal (GI), renal, and respiratory routes. The prolonged effects of disulfiram occur not only because the drug is slowly eliminated from the body but also because it irreversibly inhibits aldehyde dehydrogenase. In order to regain the ability to metabolize acetaldehyde, the individual must therefore synthesize new stores of the enzyme.
Disulfiram metabolites cause clinically important effects in the body (see Media file 2).
Disulfiram, prodrug for active metabolites.
The most important toxic metabolites are diethyldithiocarbamate (DDC) and its metabolite carbon disulfide (CS2). DDC chelates copper, thus impairing the activity of dopamine beta-hydroxylase, an enzyme that catalyzes the metabolism of dopamine to norepinephrine. In this way, DDC causes depletion of presynaptic norepinephrine and accumulation of dopamine. Although hypotension from the disulfiram-ethanol reaction is mainly attributable to the effects of acetaldehyde, depletion of the potent vasoconstrictor norepinephrine may also be a contributing factor.
Dopamine agonism may be implicated in some of the altered behavior associated with disulfiram toxicity. Although no studies have directly examined the effects of low doses of disulfiram on psychotic symptoms, hypomania and psychosis have been documented in many reports among alcoholics taking high-dose disulfiram (up to 2,000 mg/d). It is possible that disulfiram, like L-dopa and amphetamine, unmasks or exacerbates preexisting psychotic symptoms in susceptible individuals by increasing central dopamine levels.
Neurotoxic effects associated with disulfiram include extrapyramidal symptoms, and lesions of the basal ganglia have been described in patients after therapy with disulfiram. Potential mechanisms for disulfiram-associated neurotoxicity include abnormal CNS metal accumulation from the chelation of copper by DDC, leading to free radical formation and neuronal oxidative stress. In addition, one study found that disulfiram and DDC increase the release of glutamate from striato-cortical synaptic vesicles, both in vitro and in rats, suggesting yet another possible mechanism for DDC-mediated neuronal damage.2
Other mechanisms implicated in DDC’s cytotoxic effects include its ability to chelate nickel, to interfere with sulfhydryl groups in cytochrome P-450 enzymes, and to inhibit ADH and ALDH enzymes. Furthermore, DDC inhibits superoxide dismutase, thereby impairing the ability to eliminate free radicals. DDC-induced methemoglobinemia can also occur secondary to impairment (consumption) of glutathione-dependent methemoglobin reduction.
Carbon disulfide (CS2), another disulfiram metabolite from DDC metabolism, has neurotoxic effects when administered directly. Acute exposure to CS2 causes rapid onset of headache, confusion, nausea, hallucinations, delirium, seizures, coma, and potentially death. CS2 may cause seizures by interacting with pyridoxal-5-phosphate, a cofactor in the production of GABA from glutamate, thereby depleting GABA levels in the brain and leading to benzodiazepine-resistant seizures; this forms the basis for an important experimental rat model of status epilepticus. In addition to its neurotoxic effects (neurobehavioral toxin), CS2 is hepatotoxic, inhibits cytochrome P-450, and is cardiotoxic.
The mechanism by which chronic disulfiram therapy produces hepatotoxicity is not well understood and may involve hypersensitivity or immunologic reactions in addition to the direct cytotoxic effects of its metabolites.
Mortality/Morbidity
Disulfiram toxicity has a particular classification with significant overlap. The first type of toxicity is the classic disulfiram-ethanol reaction, known as the acetaldehyde syndrome. Secondly, disulfiram has its own associated acute and chronic adverse drug reactions. Finally, disulfiram-like reactions are associated with many other substances that have an ethanol-like mechanism of toxicity with disulfiram.
- Disulfiram is usually prescribed at an initial dose of 500 mg/d for 1-2 weeks, followed by a maintenance dose of 125-500 mg/d. Close monitoring for adverse reactions is required.
- Disulfiram use is associated with adverse reactions at a rate of approximately 1 per 200-2000 each year. Frequently reported aversive reactions are mainly hepatic, neurologic, dermatologic, and psychiatric.
- Drowsiness is the most common side effect and occurs in up to 5% of patients. It generally resolves after 2 weeks of treatment. Other side effects include dyspnea, sweating, alteration of taste, vasodilation, impotence, amblyopia, dizziness, headache, ataxia, polyneuritis, psychosis, and hypertension.
- Acute disulfiram overdose is uncommon. In adults, clinical manifestations after acute overdose are rare with doses less than 3 g. Ingestion of 10-30 g may be lethal. Toxicity in children has been reported after ingestion of 2.5 g of disulfiram. Symptoms of overdose in children are mostly neurologic.
Clinical
History
The disulfiram-ethanol reaction (DER) is the classic manifestation of patients with disulfiram toxicity. This reaction occurs after the ingestion of even small amounts of ethanol with the concomitant use of disulfiram or disulfiramlike agents. Disulfiram toxicity may also occur in the absence of ethanol exposure. Direct toxic effects are seen with both chronic use and acute massive ingestion.
- Ethanol blood levels as low as 5-10 mg/dL can precipitate a disulfiram-ethanol reaction; 120-150 mg/dL can lead to unconsciousness.
- Patients may experience DER signs and symptoms after the ingestion of ethanol-containing foods, medications, and products (eg, over-the-counter cough medications, mouthwash, facial-cleaning products, liquid herbal extracts).
- Some common medications that contain an ethanol concentration greater than 5% include Adult Tylenol liquid, Benadryl Elixir, Comtrex, Donnatal Elixir, Dramamine Liquid, Geritol Liquid, NyQuil Liquid, Formula 44 Cough Mixture, and Tylenol & Codeine Elixir.
- In general, the severity and duration of a reaction depend on the amount of ethanol ingested, the dosage and duration of disulfiram therapy, and individual sensitivity.
- DER symptoms usually occur within 15-30 minutes of ethanol ingestion and last for several hours. Peak effects occur within 8-12 hours.
- DER may occur within 3 hours of a disulfiram dose and up to 2 weeks following discontinuance of disulfiram.
- Lethal DERs have been reported; however, most DER cases are mild and patients recover without serious sequelae.
- Obtain a detailed organ-specific history for proper diagnosis and management of disulfiram toxicity due to chronic use or acute massive ingestion.
- Neurologic toxicity increases with dose and duration of therapy and includes the following:
- Central and peripheral sensory motor neuropathy3
- Diffuse toxic axonopathy
- Psychosis - Limbic system stimulation by dopamine
- Choreoathetosis - Basal ganglia stimulation by dopamine
- Parkinsonism - Caused by low-density lesions in the basal ganglia
- Catatonia - Occurs more often with chronic toxicity than with acute toxicity
- Movement disorders - From dopamine excess, an enhanced excitotoxic effect of glutamate and calcium-mediated cell death
- Dermatologic toxicity - Peaks at about 2 weeks of treatment; exfoliative dermatitis and allergic dermatitis (may be an unrecognized nickel allergy)
- Gastrointestinal toxicity
- Rotten-egg odor on breath (sulfide metabolites), garliclike or metallic aftertaste in mouth
- Hypersensitive or toxic hepatitis - Peaks at about 2 months of therapy and has a fatality rate of approximately 1 in 25,000 cases
- A retrospective review of the use of disulfiram among alcoholic patients being treated for active tuberculosis with isoniazid-containing regimens found no increased hepatotoxicity in patients taking both disulfiram and isoniazid. However, conclusions from this study are limited due to the retrospective nature and the very small sample size (13 patients) of the study.4
- Cholestatic jaundice
- Ophthalmologic toxicity - Optic neuritis (atrophy)
- Hematologic toxicity - Agranulocytosis, eosinophilia, thrombocytopenia, and methemoglobinemia
- Neurologic toxicity increases with dose and duration of therapy and includes the following:
Physical
- Acetaldehyde syndrome
- Head, neck, and chest flushing - Histamine-induced vasodilation
- Throbbing headaches
- Nausea, vomiting (may be refractory), diarrhea, and abdominal pain
- Weakness, dizziness, confusion, and anxiety
- Vertigo and ataxia
- Orthostatic hypotension - Hypotensive flushing reaction with warm extremities
- Diaphoresis
- Palpitations and dysrhythmias
- Pruritus
- Refractory cyanosis (eg, methemoglobinemia)
- Signs and symptoms of acute disulfiram overdose in adults and children include the following:
- Hypotension, tachycardia, and dyspnea
- Abdominal pain, nausea, vomiting, and sulfur or garlic odor on breath
- Agitation, dysarthria, chorea, hallucinations, and lethargy
- Coma and seizures
- Parkinsonlike syndrome (eg, dystonia, spastic tetraparesis)
- Polyneuropathy
- Hypersensitive hepatitis and hepatic failure
- Loss of developmental milestones
Causes
- Agents that may produce disulfiramlike reactions with ethanol include the following:
- Industrial solvents ("degreasers' flush")
- Mushrooms (eg, Coprinus atramentarius [inky cap], Clitocybe claviceps)
- Antibiotics (eg, metronidazole, sulfonamides, some cephalosporins, nitrofurantoin, chloramphenicol)
- Pesticides (eg, carbamates, monosulfiram [Tetmosol])
- Chloral hydrate
- Antifungals (griseofulvin)
Differential Diagnoses
| Anaphylaxis | Toxicity, Medication-Induced Dystonic
Reactions |
| Delirium Tremens | Toxicity, Mushroom - Disulfiramlike
Toxins |
| Dermatitis, Contact | Toxicity, Mushroom - Gyromitra Toxin |
| Gastroenteritis | Toxicity, Mushrooms |
| Headache, Tension | Toxicity, Mushrooms |
| Hepatitis | Toxicity, Scombroid |
| Methemoglobinemia | Urinary Obstruction |
| Shock, Cardiogenic | Withdrawal Syndromes |
| Shock, Hypovolemic | |
| Syncope | |
| Toxicity, Ciguatera |
Other Problems to Be Considered
Metaldehyde toxicity
Workup
Laboratory Studies
- For suspected disulfiram toxicity, the following laboratory studies should be obtained:
- Glucose level
- Electrolyte levels
- Renal function tests
- Liver function tests
- Ethanol level
- Acetaminophen level
- Arterial blood gas analysis
- Methemoglobin level (%)
Imaging Studies
- CT of the head and/or MRI studies are valuable in demonstrating CNS involvement (eg, basal ganglia ischemia, infarction) as well as in excluding other causes of altered mental status.
Other Tests
- Specific laboratory studies generally have little value in the treatment of acute toxicity. In addition, results are not usually available in a timely fashion.
- Other specific laboratory studies to consider are as follows:
- Acetaldehyde level test (toxic level >5 mg/L)
- DDC level test
- CS2 level test
- Tetraethylthiuram level (disulfiram level) test
Procedures
- In patients with hypotension and/or tachycardia, an ECG may assist in the assessment of potential end-organ damage as well as the exclusion of other possible causes of the patient's symptoms.5
Treatment
Prehospital Care
For patients with possible disulfiram-ethanol reaction, the following should be performed:
- Provide supplemental oxygen, obtain intravenous access, and place all patients on a monitor. Administer thiamine, glucose, and naloxone to patients with altered mental status, as needed.
- Intravenous fluids should be instituted if hypotension, tachycardia, or severe vomiting is present.
- Patients with coma or a severely altered mental status should be intubated for airway protection. The frequent occurrence of vomiting secondary to DER places these patients at high risk for aspiration.
Emergency Department Care
ED treatment of disulfiram-ethanol reaction (DER) is primarily supportive. No specific antidote has been tested for efficacy in the treatment of DER or acute disulfiram overdose, though fomepizole has the theoretical benefit of blocking ethanol metabolism to acetaldehyde and may be a useful therapy in patients presenting with DER. Patients with a severely altered mental status or coma should be intubated for airway protection. The risk of aspiration in patients with DER is high.
- Mild sedation with benzodiazepines may be useful in the agitated patient, and benzodiazepines may be used to treat seizures. However, sedation of patients with intractable vomiting increases the risk of aspiration and its sequelae and should be approached with caution. Benzodiazepines also have the potential to exacerbate hypotension.
- In cases of intractable vomiting, phenothiazine use must be considered cautiously because their alpha-blockade effect may worsen or induce hypotension. Metoclopramide, ondansetron, or granisetron are considered the antiemetics of choice in these cases.
- Intravenous fluids should be given to patients experiencing a DER to replace volume losses from emesis and third spacing of intravascular fluid.
- Intravenous fluids and vasopressors are indicated to support blood pressure and treat patients who are in shock.
- Decontamination procedures are not likely to be beneficial once the reaction begins. Consider gastric emptying only in the hospital setting with cases of massive ethanol ingestion in which a patent and protected airway can be maintained.
- Inducing emesis with ipecac syrup is not recommended. Ipecac syrup contains ethanol, which could precipitate DER. Emesis may delay administration of activated charcoal, worsen the nausea and vomiting associated with disulfiram toxicity, and increase the likelihood of pulmonary aspiration if seizures and coma suddenly occur.
- In acute disulfiram overdose, consider the use of activated charcoal, if available and if the patient is alert and able to drink it safely. Use of multiple dose activated charcoal (MDAC) may be beneficial.
- Multiple dose activated charcoal can increase the rate of elimination of disulfiram and its metabolites that undergo enterohepatic recirculation. Activated charcoal is not indicated for disulfiramlike syndromes, and it is not indicated for the treatment of DER.
- The risk-benefit of administering charcoal to a patient with altered mental status and a high likelihood of vomiting and potential aspiration must be carefully weighed.
- In severe DER, hemodialysis may be indicated to enhance the elimination of ethanol and acetaldehyde. Neither hemodialysis nor hemoperfusion has been beneficial for treatment of acute disulfiram overdose.
- Some authors have suggested that fomepizole (Antizol) may be beneficial in cases of severe DER. Fomepizole is a potent inhibitor of alcohol dehydrogenase that may limit the metabolism of ethanol by this enzyme and thereby prevent further accumulation of acetaldehyde. No studies have examined the utility of fomepizole in this context; however, a theoretical benefit exists in patients taking disulfiram who present with DER after a large ethanol ingestion.
Consultations
- Consult with the local poison control center or a medical toxicologist.
Medication
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
GI decontaminant
These agents are empirically used to minimize systemic absorption of the toxin.
Activated charcoal (Liqui-Char)
Most useful if administered within 90 min of ingestion. Repeat doses may be used, especially with ingestion of sustained-release agents. Limited outcome studies exist, especially when administration is more than 1 h postingestion.
Administration of charcoal by itself (in aqueous solution), as opposed to coadministration with a cathartic, is becoming the current practice standard. This is because studies have not shown benefit from cathartics, and, while most drugs and toxins are absorbed within 30-90 min, laxatives take hours to work. Dangerous fluid and electrolyte shifts have occurred when cathartics are used in small children.
When ingested dose is known, charcoal may be administered at 10 times ingested dose of agent, over 1 or 2 doses.
Dosing
Adult
1 g/kg PO/NG (50-75 g usual dose); may administer 0.5 g/kg PO/NG as repeat dose if desired
Cathartic not recommended
Pediatric
Administer as in adults (12.5-25 g usual dose)
Cathartic not recommended
Interactions
May inactivate ipecac syrup if used concomitantly; effectiveness of other medications decreases with coadministration; decreased levels occur with coadministration of sherbet, milk, or ice cream
Contraindications
Documented hypersensitivity; poisoning or overdose of mineral acids and alkalies; unprotected airway with absent gag reflex or compromised ability to protect airway due to CNS depression expected
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Protect airway before administration in patients with absent gag reflex or a depressed level of consciousness; when considering repeat dosing, monitor for active bowel sounds to minimize risk of charcoal ileus
Cardiovascular agents
Treat hypotensive patients with IV crystalloid (eg, 0.9 NS or LR). If pressors are indicated, norepinephrine (Levophed) is DOC (over dopamine) because of catecholamine depletion.
Norepinephrine (Levophed)
Used in protracted hypotension following adequate fluid-volume replacement. Stimulates beta1- and alpha-adrenergic receptors, which, in turn, increases cardiac muscle contractility, heart rate, and vasoconstriction. As a result, systemic blood pressure and coronary blood flow increase.
After obtaining a response, adjust rate of flow to and maintain at a low normal blood pressure (eg, 80-100 mm Hg systolic), sufficient to perfuse vital organs.
Dosing
Adult
4-8 mcg/min IV initial; titrate prn q5-10min
Pediatric
1-2 mcg/min IV or 0.1 mcg/kg/min IV initial; titrate prn
Interactions
Arrhythmogenic in aromatic and halogenated hydrocarbon exposures; atropine may enhance the pressor response by blocking reflex bradycardia caused by norepinephrine
Contraindications
Documented hypersensitivity; peripheral or mesenteric vascular thrombosis because ischemia may be increased and area of the infarct extended
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Correct blood-volume depletion, if possible, before therapy; extravasation may cause severe tissue necrosis and, thus, should be administered into a large vein; caution in occlusive vascular disease
Antihistamines
Antihistamine improves the flushing response in DER. Diphenhydramine (H1 blocker) and cimetidine or ranitidine (H2 blockers) may be beneficial. NSAIDs (eg, Toradol) may ameliorate flushing response by blocking the synthesis of prostaglandins.
Diphenhydramine (Benadryl)
H1-receptor blocker with antiparkinsonism, antiemetic, and anticholinergic response.
Used for symptomatic relief of symptoms caused by histamine released in response to allergens.
Dosing
Adult
25-50 mg PO/IV/IM q6-8h
Pediatric
5 mg/kg/d PO/IV/IM in divided qid (0.5-1 mg/kg/dose)
Interactions
Potentiates effect of CNS depressants; because of alcohol content, do not administer syrup dosage form to patient taking medications that can cause disulfiramlike reactions
Contraindications
Documented hypersensitivity; MAOIs
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
May exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, and urinary tract obstruction; adverse effects include sedation and paradoxical excitation
Cimetidine (Tagamet)
H2 antagonist that, when combined with an H1 type, may be useful for treating itching and flushing in anaphylaxis, pruritus, urticaria, and contact dermatitis that do not respond to H1 antagonists alone. Use in addition to H1 antihistamines.
Dosing
Adult
300 mg IV/IM q6h, continuous infusion 37.5 mg/h (900 mg/d), 400 mg PO bid, or 400-800 mg qhs
Pediatric
40-60 mg/kg/d IV/IM
Interactions
Can increase blood levels of theophylline, warfarin, tricyclic antidepressants, triamterene, phenytoin, quinidine, propranolol, metronidazole, procainamide, and lidocaine
Contraindications
Documented hypersensitivity
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Elderly persons may experience confusion; may cause impotence and gynecomastia in young males; may increase levels of many drugs; adjust dose or discontinue treatment if changes in renal function occur
Ranitidine (Zantac)
H2 antagonist that, when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.
Dosing
Adult
50 mg IV q6-8h, continuous infusion at 6.25 mg/h, 150 mg PO bid, or 300 mg qhs
Pediatric
5-10 mg/kg/d
Interactions
May decrease effects of ketoconazole and itraconazole; may alter serum levels of ferrous sulfate, diazepam, nondepolarizing muscle relaxants, and oxaprozin
Contraindications
Documented hypersensitivity
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Caution in renal or liver impairment; if changes in renal function occur during therapy, consider adjusting dose or discontinuing treatment
Pharmacologic Antidotes
NSAIDs may benefit by reducing the severity of the flushing response. Pyridoxine (vitamin B-6) may be useful in patients who demonstrate evidence of neurological toxicity or intractable seizures.
Ketorolac (Toradol)
Inhibits prostaglandin synthesis by decreasing the activity of cyclooxygenase, which results in decreased formation of prostaglandin precursors.
Dosing
Adult
Load 30-60 mg IV/IM, then 15-30 mg IV/IM q6-8h (60-120 mg/d) or 10-20 mg PO first dose, then 10 mg PO q4-6h, not to exceed 40 mg/d
>65 y: Use lower doses within dosing range; do not exceed 2 wk duration of therapy
Pediatric
Not established
Interactions
Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Contraindications
Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; do not administer into CNS
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Precautions
Acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low WBC counts (rare), usually return to normal during ongoing therapy; discontinue therapy if leukopenia, granulocytopenia, or thrombocytopenia persists
Pyridoxine (Nestrex)
Used in the treatment of pyridoxine-dependent seizures. Involved in synthesis of GABA within CNS.
Dosing
Adult
1 g IV initial; repeat prn
Pediatric
500 mg IV initial; repeat prn
Interactions
May decrease levodopa, phenytoin, and phenobarbital serum levels; may act synergistically with benzodiazepines
Contraindications
Documented hypersensitivity
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
>200 mg/d may precipitate withdrawal effects when medication discontinued
Antiemetics
These agents are useful in cases of vomiting to mitigate symptoms and to avoid volume depletion.
Metoclopramide (Reglan)
A promotility agent that increases gastric contractions, relaxes the pyloric sphincter and duodenal bulb, and increases peristalsis in the duodenum and jejunum. Exact mechanism is unknown, but metoclopramide may increase gastric emptying and decrease intestinal transit time by sensitizing tissues to the effects of acetylcholine. Has little or no effect on gastric, biliary, or pancreatic secretions, or on colon or gallbladder motility.
Dosing
Adult
10 mg IV/IM q2-3h prn
Pediatric
0.4-0.8 mg/kg/d PO/IV/IM divided qid; not to exceed to 5 mg/dose
Interactions
Sedative effects may be potentiated by CNS depressants such as ethanol and benzodiazepines; promotility effects of metoclopramide are antagonized by anticholinergic and opioid drugs; decreased gastric transit time may decrease absorption of drugs (eg, digoxin) or increase absorption of drugs from small intestine (eg, acetaminophen, tetracycline, ethanol, levodopa); caution in patients taking MAOIs because of increased catecholamine release caused by metoclopramide
Contraindications
Documented hypersensitivity; GI hemorrhage, perforation, or obstruction; pheochromocytoma
Relative contraindications include seizure disorder or presence of other drugs likely to cause extrapyramidal symptoms or NMS
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Associated with suicidal ideation in patients with history of depression; dystonic reactions may be observed; neuroleptic malignant syndrome reported; long-term use, particularly in elderly persons, may be associated with tardive dyskinesia; since metoclopramide may induce release of catecholamines and is associated with transient rise in plasma aldosterone may cause hypertension or volume overload in patients with history of hypertension, cirrhosis, or CHF; metoclopramide is largely excreted renally, and dose should be lowered in patients with renal impairment
Ondansetron (Zofran)
Selective antagonist of serotonin 5HT3 receptors generally used to control chemotherapy-associated and postoperative nausea and vomiting. Precise mechanism of action is not known; however, ondansetron is thought to block either vagal stimulation of serotonin release in the central chemoreceptor trigger zone of the area postrema, or a vagally mediated vomiting reflex caused by release of serotonin from enterochromaffin cells of small intestine and stimulation of peripheral 5HT3 receptors, or both.
Dosing
Adult
4 mg IV over 30 sec to 5 min
Pediatric
4-12 years: 100 mcg/kg IV over 30 sec to 5 min
>40 kg: 4 mg IV
Interactions
Ondansetron is metabolized by hepatic cytochrome P-450 enzymes (CYP3A4, CYP2D6, CYP1A2); clearance is significantly increased by potent inducers of CYP3A4 (carbamazepine, phenytoin, rifampicin), but no dosage adjustments have been recommended for patients on these medications
Contraindications
Patients with previous hypersensitivity reactions to ondansetron or other 5HT3 antagonists
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Safety and clearance of ondansetron in patients with hepatic failure not studied, and its safety has not been studied in pregnancy or in children <3 y; increases large bowel transit time and should be used with caution in patients with possible subacute small-bowel obstruction; most frequently reported adverse effects are headache, constipation, and flushing; rare cases of tachycardia, bradycardia, hypotension, syncope, seizure, angina, and ECG abnormalities reported
Granisetron (Kytril)
An antinauseant and antiemetic available in PO and IV forms for use in severe postoperative and chemotherapy/radiation therapy-induced nausea. Granisetron is a selective antagonist of serotonin 5HT3 receptors. Precise mechanism of action not known; however, thought to block either vagal stimulation of serotonin release in central chemoreceptor trigger zone of area postrema, or a vagally mediated vomiting reflex caused by release of serotonin from enterochromaffin cells of small intestine and stimulation of peripheral 5HT3 receptors.
Dosing
Adult
10 mcg/kg IV over 5 min
Pediatric
Not established
Interactions
CYP-450 3A substrate, inducers (eg, phenobarbital) may decrease effect, while inhibitors (eg, erythromycin, clarithromycin) may increase toxicity
Contraindications
Documented hypersensitivity
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Caution in liver disease
Follow-up
Further Inpatient Care
- Monitor all patients with DER or acute disulfiram overdose for a minimum of 8-12 hours, even if they lack significant signs or symptoms of toxicity.
- Admit patients to the ICU if they demonstrate signs and symptoms of significant toxicity.
Further Outpatient Care
- Prompt follow-up care with the primary care physician responsible for treating the patient's alcoholism should be arranged for all patients presenting with DER or disulfiram toxicity prior to discharge.
- Patients with alcoholism who are treated with disulfiram must wear a medic alert bracelet indicating its usage.
- Refer patients with alcoholism to an alcoholic detoxification center and advise them not to drink alcohol or consume any medication or product containing alcohol for at least 2 weeks after the last dose of disulfiram.
- A psychiatrist should evaluate all patients being treated for overdose before discharge.
Patient Education
- For excellent patient education resources, visit eMedicine's Poisoning - First Aid and Emergency Center, Substance Abuse Center, and Mental Health and Behavior Center. Also, see eMedicine's patient education articles Poisoning, Activated Charcoal, Alcoholism, and Substance Abuse.
Miscellaneous
Medicolegal Pitfalls
- Failure to remember that medicines, foods, and other consumer products may contain alcohol and precipitate DER
- Disulfiram should only be prescribed to alcoholic persons in a monitored detoxification or therapy setting and not by emergency physicians, who cannot provide adequate follow-up care to these patients.
Multimedia
Media file 1: The pathway of ethanol metabolism. Disulfiram reduces the rate of oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on aldehyde dehydrogenase (ALDH).
Media file 2: Disulfiram, prodrug for active metabolites.
References
Baker JR, Jatlow P, McCance-Katz EF. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. Mar 16 2007;87(2-3):202-9. [Medline].
Vaccari A, Ferraro L, Saba P, et al. Differential mechanisms in the effects of disulfiram and diethyldithiocarbamate intoxication on striatal release and vesicular transport of glutamate. J Pharmacol Exp Ther. Jun 1998;285(3):961-7. [Medline].
Filosto M, Tentorio M, Broglio L, et al. Disulfiram neuropathy: two cases of distal axonopathy. Clin Toxicol (Phila). Apr 2008;46(4):314-6. [Medline].
Burman WJ, Terra M, Breese P, et al. Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. Int J Tuberc Lung Dis. Sep 2002;6(9):839-42. [Medline].
Milne HJ, Parke TR. Hypotension and ST depression as a result of disulfiram ethanol reaction. Eur J Emerg Med. Aug 2007;14(4):228-9. [Medline].
de Mari M, De Blasi R, Lamberti P, et al. Unilateral pallidal lesion after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord. Apr 1993;8(2):247-9. [Medline].
Ellenhorn MJ. Disulfiram. In: Ellenhorn's Medical Toxicology. Vol 2. Lippincott Williams & Wilkins; 1997:1356-62.
Enghusen Poulsen H, Loft S, Andersen JR, et al. Disulfiram therapy--adverse drug reactions and interactions. Acta Psychiatr Scand Suppl. 1992;369:59-65; discussion 65-6. [Medline].
Forns X, Caballeria J, Bruguera M, et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol. Nov 1994;21(5):853-7. [Medline].
Heath MJ, Pachar JV, Perez Martinez AL, et al. An exceptional case of lethal disulfiram-alcohol reaction. Forensic Sci Int. Sep 1992;56(1):45-50. [Medline].
Hirschberg M, Ludolph A, Grotemeyer KH, et al. Development of a subacute tetraparesis after disulfiram intoxication. Case report. Eur Neurol. 1987;26(4):222-8. [Medline].
Kirubakaran V, Faiman MD, Liskow B, et al. Plasma measurements of disulfiram and its metabolites in a case of severe disulfiram-ethanol reaction. Psychiatr J Univ Ott. Sep 1986;11(3):166-8. [Medline].
Krauss JK, Mohadjer M, Wakhloo AK, et al. Dystonia and akinesia due to pallidoputaminal lesions after disulfiram intoxication. Mov Disord. 1991;6(2):166-70. [Medline].
Kuffner EK. Disulfiram and disulfiram-like reactions. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS. Goldfrank's Toxicology Emergencies. 8th ed. McGraw-Hill; 2006:1176-1183.
Laplane D, Attal N, Sauron B, et al. Lesions of basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry. Oct 1992;55(10):925-9. [Medline].
Mahajan P, Lieh-Lai MW, Sarnaik A, et al. Basal ganglia infarction in a child with disulfiram poisoning. Pediatrics. Apr 1997;99(4):605-8. [Medline].
Nasrallah HA. Vulnerability to disulfiram psychosis. West J Med. Jun 1979;130(6):575-7. [Medline].
Stransky G, Lambing MK, Simmons GT, et al. Methemoglobinemia in a fatal case of disulfiram-ethanol reaction. J Anal Toxicol. Mar-Apr 1997;21(2):178-9. [Medline].
Zorzon M, Mase G, Biasutti E, et al. Acute encephalopathy and polyneuropathy after disulfiram intoxication. Alcohol Alcohol. Sep 1995;30(5):629-31. [Medline].
Keywords
disulfiram toxicity, disulfiram, disulfiram poisoning, disulfiram exposure, alcohol treatment, Antabuse, acetaldehyde syndrome, disulfiram-ethanol reaction, DER, tetraethylthiuram disulfide, TETD, management of alcoholism, deterrent to ethanol abuse
Contributor Information and Disclosures
Author
Samara Soghoian, MD, MA, Clinical Assistant Professor of Emergency Medicine, New York University School of Medicine, Bellevue Hospital Center
Samara Soghoian, MD, MA is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Coauthor(s)
Sage W Wiener, MD, Assistant Professor, Department of Emergency Medicine, State University of New York Downstate, Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center
Sage W Wiener, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
José Eric Díaz-Alcalá, MD, FAAEM,, Consulting Staff in Medicine Service, Division of Emergency Medicine/Medical Toxicology, Veterans Affairs Caribbean Healthcare System; Medical Director, Puerto Rico Poison Control Center, San Juan, Puerto Rico
José Eric Díaz-Alcalá, MD, FAAEM, is a member of the following medical societies: American Academy of Emergency Medicine and American College of Medical Toxicology
Disclosure: Nothing to disclose.
Medical Editor
David C Lee, MD, Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School
David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Pharmacy Editor
John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals
John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.
Managing Editor
John G Benitez, MD, MPH, FACMT, FACPM, FAAEM, Associate Professor, Department of Medicine, Clinical Pharmacology Division, Vanderbilt University; Managing Director, Tennessee Poison Center
John G Benitez, MD, MPH, FACMT, FACPM, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society
Disclosure: Nothing to disclose.
CME Editor
John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Chief Editor
Asim Tarabar, MD, Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital
Disclosure: Nothing to disclose.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)